Therefore, our data of increased TOP2A expression and increased sensitivity to doxorubicin in E2 exposed cells further supports the view that higher levels of TOP2A serve as target for doxorubicin and facilitates the increased cytotoxic effects of doxorubicin in cancer cells. This evidence concerns the gene TOP2A and cancer.